Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Warnke, PH; Humpe, A; Strunk, D; Stephens, S; Warnke, F; Wiltfang, J; Schallmoser, K; Alamein, M; Bourke, R; Heiner, P; Liu, Q.
A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies.
J Craniomaxillofac Surg. 2013; 41(2):153-161
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Schallmoser Katharina
Strunk Dirk
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
The transplantation of human stem cells seeded on biomaterials holds promise for many clinical applications in cranio-maxillo-facial tissue engineering and regenerative medicine. However, stem cell propagation necessary to produce sufficient cell numbers currently utilizes fetal calf serum (FCS) as a growth supplement which may subsequently transmit animal pathogens. Human platelet lysate (HPL) could potentially be utilized to produce clinical-grade stem cell-loaded biomaterials as an appropriate FCS substitute that is in line with clinically-applicable practice. The goal of this study was to investigate whether HPL can be successfully used to propagate human mesenchymal stem cells (HMSCs) seeded on clinically-approved collagen materials under clinically-applicable conditions using FCS as a control. HMSCs were isolated from bone marrow and cultured in the presence of 10% FCS or 10% HPL. Characterization of HMSCs was performed by flow cytometry and through osteogenic and adipogenic differentiation assays. Proliferative capacity of HMSCs on both matrices was investigated by mitochondrial dehydrogenase assays (WST) and tissue coverage scanning electron microscopy (SEM). The isolated HMSC differentiated into osteogenic and adipogenic cells authenticating the multipotentiality of the HMSCs. WST tests and the SEM images demonstrated that HPL was generally superior to FCS in promoting growth of seeded HMSCs. For all other tests HPL supported HMSCs at least equal to FCS. In conclusion, HPL is an effective growth factor to allow expansion of clinical-grade HMSCs on clinically-approved biomaterials for maxillofacial and oral implantology applications.
Find related publications in this database (using NLM MeSH Indexing)
Adipogenesis - physiology
Biocompatible Materials - chemistry
Blood -
Blood Platelets - chemistry
Bone Marrow Cells - physiology
Cell Culture Techniques -
Cell Differentiation - physiology
Cell Lineage - physiology
Cell Proliferation -
Cell Survival - physiology
Collagen - chemistry
Feasibility Studies -
Flow Cytometry -
Fluorescein-5-isothiocyanate - diagnostic use
Fluorescent Dyes - diagnostic use
Formazans - diagnostic use
Humans -
Intercellular Signaling Peptides and Proteins - therapeutic use
Male -
Mesenchymal Stromal Cells - physiology
Microscopy, Electron, Scanning -
Middle Aged -
Multipotent Stem Cells - physiology
Osteogenesis - physiology
Regeneration - physiology
Tetrazolium Salts - diagnostic use
Time Factors -
Tissue Scaffolds - chemistry

Find related publications in this database (Keywords)
Human mesenchymal stem cells
MSC
Tissue engineering
Clinically-applicable practice
Regenerative
Regeneration
FCS
Stem cell
Translational
Protocol
© Meduni Graz Impressum